The new crown drug trial identified a second mortality-reducing compound

the world's largest COVID-19 drug trials have shown that the anti-inflammatory drug Tocilizumab reduces the risk of death in patients hospitalized with new crowns, reduces the need for ventilators, and reduces the length of stay in hospitals. The results were announced on February 11th local time in the UK's Randomized Assessment of COVID-19 Therapy (COVID-19 Therapy, RECOVERY) trial, and a preprint of the data was published on medRxiv.
," said Atimalaipet Ramanan, a rheumatologist at the University of Bristol in the UK, according to Science. Ramanan was not involved in the study, but she is a member of the Indian Association of
s toads. She said it could be the second drug to reduce the death rate of the new crown after the steroid dexamisong.
, a pharmacist at the University of Michigan at Ann Arber and president of the Society of Infectious Disease Pharmacists, added in an interview with Science that it would be "fantastic news" if the data were reliable.
but the price of the toad is about 100 times that of dexamisson, raising questions again about how to ensure that the global population can benefit from it.
, which is used to treat rheumatoid arthritis and other autoimmune diseases, is a monoclonal antibody that blocks proteins that act as receptors for the immune system's signaling molecule, naloxin 6 (IL-6).
can weaken the immune response, which is often overactive in patients with COVID-19, leading to serious illness and even death.
the UK's RANDOMD-19 therapy randomized assessment (The Randomized Evaluation of COVID-19 Therapy, RECOVERY) trial is the world's largest trial of COVID-19 therapy and has so far recruited more than 36,000 patients at more than 170 clinics in the UK, Science reported. In addition to identifying two successful drugs, misycisone and toroquine, it ruled out several other drugs, including antimalarial hydroxychloroquine, the
toxic drugs Lopinavir/Litonave and azithromycin ( an antibiotic).
the pandemic began, doctors began testing the effects of toad monoantial therapy COVID-19 in small clinical trials. Previously, the scientific community was encouraged when rehabilitation trials in the UK in June 2020 showed that dexamisson had reduced the mortality rate for new crown inpatients by as much as a third. Desemisson quickly became part of the standard of care.
Horby, the leading researcher in the RANDOM evaluation trial of COVID-19 therapy in the UK, said in a press release that corticosteroids such as dexamisong were seen as roughly the right direction - to lower the human immune system. "We're looking for highly targeted drugs right now."
the trial, 2,022 patients were randomly assigned to receive toad monoantial therapy and compared with 2,094 patients who received routine care at random. Eighty-two percent of patients also received dexamisson.
28 days, 596 patients died in the toad group, compared with 694 in the control group. This means that toad monoantials reduce mortality from 33% to 29%.
a 4 percent reduction in topolycerid resistance may seem to have little effect compared to dexamisson, but "an absolute 4 percent reduction in mortality is not insignificant," brown university's School of Public Health
Ashish Jha said. Jha says the success of dexamisson may raise unrealistic expectations about other drugs. In fact, the analysis shows that the advantages of toad monoantial should be greater than steroid drugs.
Another COVID-19 therapy randomized assessment trial participant, Martin Landray, said in a press release that the reduction in mortality from toads can benefit people, whether young, men, women, or races. The drug significantly reduces the probability that COVID-19 patients will develop into a need for invasing mechanical aer than those with mechanical aertics.
results of the early COVID-19 test of toad monoantitor were mixed, but smaller than Recovery. The results of the recently released REMAP-CAP trial for community-acquired pneumonia have convinced some doctors that the drug is beneficial, Pogue wrote. "Given the uneven data from previous clinical trials, others are waiting to recover," he wrote. "Although the REMAP-CAP trial only included the most sick patients, recovery results showed that the benefits also applied to patients with milder conditions.
, however, the drug costs much more than dexamisong: in the UK, it costs around 500 pounds per course of treatment, while steroid-type miscedyson costs 5 pounds.